This is a preview of subscription content, log in via an institution to check access.
References
1. Stellato D, et al. Cost-Effectiveness of Ribocilib plus Nonsteroidal Aromatase Inhibitor (NSAI) in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer (ABC)- a Canadian Healthcare Perspective. 25th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. N/A, 18 May 2020. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/intl2020-3182/101166
2. Jeong E, et al. Cost-Effectiveness of Ribociclib plus Endocrine Therapy in Treating Premenopausal or Perimenopausal Women with HR-Positive, HER2-Negative Advanced Breast Cancer in the United States. 25th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. N/A, 18 May 2020. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/intl2020-3182/102548
3. Stellato D, et al. Cost-Effectiveness of Ribocilib plus Fulvestrant (R+F) vs Fulvestrant (FUL) in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer (ABC)- a Canadian Healthcare Perspective. 25th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. N/A, 18 May 2020. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/intl2020-3182/100780
Rights and permissions
About this article
Cite this article
Ribociclib for HR+/HER2- ABC: cost effective in Canada or USA?. PharmacoEcon Outcomes News 855, 26 (2020). https://doi.org/10.1007/s40274-020-6891-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6891-5